Compare Automatic Data Processing Inc (ADP) vs Eli Lilly And Co (LLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Automatic Data Processing Inc vs Eli Lilly And Co — how do they compare? Automatic Data Processing Inc trades at $241.94 (market cap $98.17B), while Eli Lilly And Co trades at $1,222.08 (market cap $1.10T). The key difference: Eli Lilly And Co is far larger — about 11.2× Automatic Data Processing Inc's market cap, and Automatic Data Processing Inc pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| ADP | LLY | |
|---|---|---|
Market Cap | $98.17B | $1.10T |
Sector | Industrials | Health |
52-Week High | $310.94 | $1.24K |
52-Week Low | $188.79 | $625.65 |
Enterprise Value | $99.24B | $1.14T |
Dividend Yield | 2.77% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADP trades at $245.60, up 1.37% on the day, near its 52-week high. The stock shows bullish technical signals with consistent earnings beats in recent quarters. Revenue grew to $20.56 billion in 2025, with a net income margin of 20.12%. Analyst sentiment is mixed, with a consensus hold rating but a technical outlook suggesting strength. The company maintains strong profitability metrics and recently announced a dividend payment.
Outlook remains stable with projected revenue growth to $21.6 billion in 2026. Risks include competitive pressures and economic sensitivity. Opportunities lie in AI integration and margin expansion. The stock offers value through dividends and steady performance, though valuation multiples are elevated relative to historical averages.
Eli Lilly (LLY) trades at $1,235.56, up 2.07% today, with a bullish technical signal and strong earnings momentum, having beaten EPS estimates for three consecutive quarters. Revenue surged to $65.18B in 2025, with a net income margin of 34.99%, while analyst consensus is strongly positive with a $1,310 price target. Recent news highlights expansion in China for its breast cancer drug and bullish commentary from financial media on growth prospects.
The outlook remains favorable due to robust revenue growth and high profitability, though elevated valuation ratios and regulatory risks pose challenges. Upside is supported by analyst optimism and institutional interest, but investors should monitor competitive pressures and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Automatic Data Processing Inc
ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 990,000 clients primarily in the United States. ADP's employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.
Read more on ADP →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
